RT @doctorRBC: No significant difference in malignancy risk in patients with rheumatic disease and a prior history of ma
Tweet Content
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Show on Archive Page
On
Display in Search Results
On
PDQ
Off